Clinical Outcomes Data
The measurement program behind MindScape Retreat's Methadone/Suboxone Transition Protocol: validated withdrawal and craving instruments scored from admission through scheduled follow-up.
Transitioning patients off medication-assisted treatment presents pharmacological challenges that distinguish this cohort from all other ibogaine protocols. Methadone's full mu-opioid agonist activity, 24 to 36 hour half-life, and significant QTc-prolonging cardiovascular effects require a carefully managed dose reduction to a safe threshold before ibogaine administration can proceed. Buprenorphine (Suboxone) presents a different set of constraints: its extraordinarily high mu-opioid receptor binding affinity, exceeding that of methadone, heroin, or oxycodone, means that residual receptor occupancy can directly block ibogaine's mechanism and precipitate paradoxical withdrawal if the transition timing is miscalculated.
The dashboard below draws its values live from our clinical records system for this program, across eight validated assessment scales scored from admission through 90-day follow-up, and it renders a trajectory only when the cohort holds real assessment data. Each line reflects the cohort-averaged score, which is what makes the recovery curves of two pharmacologically distinct populations comparable at all.
Methadone and suboxone guests are expected to trace meaningfully different response curves, which is why the two are tracked as separate groups. Methadone, with its extended half-life and the deeper receptor neuroadaptation that comes of years of full-agonist maintenance, prolongs the transition period and tends to front-load the withdrawal burden. Whether the COWS and SOWS curves of the two groups converge, and at which assessment, is exactly the question the measurement schedule exists to answer.
Suboxone guests often present with more acute early withdrawal symptoms tied to the mandatory bridging protocol, the 5 to 7 day transition off buprenorphine to short-acting opioids that precedes ibogaine administration. Any pre-ibogaine discomfort shows up in the admission and early assessments rather than being smoothed away, which is the point of scoring on a fixed schedule. Designing medication-specific pretaper and bridging protocols, rather than applying one standardized preparation pathway, is a clinical judgement the data is there to test, not a conclusion it has already delivered.
Study Overview
Two Medications. One Neurobiological Reset.
This program treats guests maintained on medication-assisted treatment (MAT) who want to discontinue opioid replacement therapy entirely. The methadone group arrives on doses that typically range from 30 to 120 mg per day, often after years of maintenance. The suboxone (buprenorphine/naloxone) group arrives on doses that typically range from 4 to 24 mg per day.
Nearly everyone in this program arrives having already attempted conventional MAT dose tapering, either self-directed or clinically supervised, without achieving lasting discontinuation. The barriers they describe are consistent: protracted withdrawal syndrome, intense drug craving, and the emergence of profound anhedonia and psychological distress during dose reduction, all well documented in the MAT discontinuation literature.
Eight validated assessment scales are tracked throughout the protocol: the Clinical Opiate Withdrawal Scale (COWS), the Subjective Opiate Withdrawal Scale (SOWS), the Objective Opiate Withdrawal Scale (OOWS), the Visual Analogue Scale for Craving (VAS_CRAVING), the Brief Substance Craving Scale (BSCS), the Visual Analogue Scale for Pain (VAS_PAIN), the Visual Analogue Scale for Sleep (VAS_SLEEP), and the Visual Analogue Scale for Wellbeing (VAS_WELLBEING). All scales are administered at baseline, 24 hours post-ibogaine, 72 hours post-ibogaine, and at 30, 60, and 90-day follow-up.
For methadone patients, the relevant baseline is not simply the withdrawal state at the moment of ibogaine administration: it is the cumulative neuroadaptation accumulated over years of full mu-opioid agonist exposure. Methadone produces particularly deep receptor downregulation and hormonal dysregulation relative to shorter-acting opioids, and its cardiovascular effects (QTc prolongation) require continuous cardiac monitoring throughout the treatment protocol. The Clinical Opiate Withdrawal Scale (COWS) and Subjective Opiate Withdrawal Scale (SOWS) in this context are measuring not just the severity of an acute withdrawal episode, but the depth of the neurobiological deficit that ibogaine must reverse.
The VAS Craving scale adds a third dimension: the psychological compulsion to re-engage with opioid replacement that drives conventional taper failure. Published data on methadone taper outcomes consistently identify craving as the dominant predictor of relapse during dose reduction, irrespective of withdrawal severity. Scoring all three measures at the same timepoints is what allows the physiological, subjective, and craving dimensions of methadone dependency to be read against each other rather than one at a time.
Years of full mu-opioid agonist maintenance is not, in our clinical experience, a bar to an ibogaine-assisted transition, but it does change the preparation. The individualized pretaper protocol exists to bring each guest to a pharmacokinetically appropriate threshold before ibogaine administration, and that is slow, calibrated work. Suboxone poses a different pharmacological challenge: not duration of exposure, but depth of receptor occupancy.
Buprenorphine's partial agonist ceiling effect means it produces less euphoria than full agonists, but its binding affinity to the mu-opioid receptor is paradoxically higher, meaning that even trace amounts of residual buprenorphine can displace or block ibogaine. The mandatory 5 to 7 day bridging protocol to short-acting opioids is therefore not merely precautionary; it is mechanistically required for the treatment to work at all. Suboxone guests are scored at the same timepoints as methadone guests, after completion of the buprenorphine clearance protocol, so that the two can be compared on equal terms.
The reason the two medications are tracked side by side is that conventional medicine treats both populations as maintenance-dependent indefinitely. On the published record, Brown & Alper (2017) synthesized 14 observational studies demonstrating consistent suppression of opioid withdrawal and craving, and Noller et al. (2017) reported 80% abstinence at one month in a New Zealand observational study of opioid dependence. Neither of those cohorts was ours, and we will not borrow their figures for our own.
What brings guests to this program is not a number. It is the prospect of a single pharmacological intervention that compresses the withdrawal timeline from months to days and addresses the craving dimension that invariably drives relapse during conventional tapering, instead of another extended and uncomfortable dose reduction. The study design, safety protocol, and measurement methodology behind the program are documented in full below.
Study Design & Methodology
Prospective observational cohort design with pre-specified subgroup analysis across methadone and buprenorphine/suboxone populations.
Prospective, single-center observational cohort with stratified enrollment by medication type. The methadone group and the buprenorphine/suboxone group are analyzed separately and combined. Written informed consent obtained from every guest. Pre-specified subgroup analysis for medication-specific outcomes.
Adults aged 18 to 60 with active MAT maintenance ≥ 12 months. Documented prior taper attempt with failure. Cardiac clearance (QTc < 450ms, particularly critical for methadone patients given methadone's known QTc-prolonging properties). Adequate hepatic/renal function. Willingness to complete supervised pretaper and 90-day follow-up.
Primary: COWS (0 to 48), SOWS (0 to 64). Secondary: OOWS (0 to 13), VAS Craving (0 to 100), BSCS (0 to 96), VAS Pain (0 to 100), VAS Sleep (0 to 10, higher = better), VAS Wellbeing (0 to 100, higher = better). All instruments validated for opioid withdrawal. Additional: MAT dose tracking, pretaper compliance, medication-free status confirmation.
Pretaper phase: weekly assessment during dose reduction (2 to 4 weeks). Treatment phase: Baseline (admission), 24h, 72h, Day 7, Day 14. Follow-up: Day 30, Day 60, Day 90. Medication-free status confirmed via self-report, prescriber confirmation, and urine drug screening at 90-day endpoint.
Pre-specified analysis comparing the methadone and suboxone cohorts across all endpoints. Between-group comparisons controlled for baseline dose equivalency, maintenance duration, and prior taper history. Multivariate regression for predictors of successful discontinuation. Nothing publishes until a cohort holds at least 20 sets of paired data.
Enhanced cardiac monitoring for methadone patients, serial QTc assessment at baseline, pre-ibogaine (post-taper), 6h, 12h, 24h, and 48h post-ibogaine. Precipitated withdrawal protocol on standby for suboxone patients in bridging phase. Adverse events documented per MedDRA. Independent safety review for all cardiac events.
Methadone vs. Suboxone
Differentiated Outcomes by Medication Type
The clinical pathway to ibogaine differs meaningfully between the methadone and suboxone cohorts, reflecting fundamental pharmacological differences between the two medications.
Methadone's full mu-opioid agonist activity and exceptionally long half-life (24 to 36 hours) make it highly effective for suppressing withdrawal but technically complex to transition from. Guests maintained on doses above 40 mg/day complete a structured 2 to 3 week pretaper to reach a threshold dose before ibogaine administration, and most methadone guests need one.
Suboxone presents a different challenge: buprenorphine's exceptionally high mu-opioid receptor binding affinity, higher than methadone or heroin, means that residual receptor occupancy can block ibogaine's mechanisms and precipitate a paradoxical withdrawal response if timing is not managed precisely. Every suboxone guest completes a mandatory bridging protocol, transitioning to short-acting opioids for 5 to 7 days before ibogaine administration to allow buprenorphine clearance. Comparing the two groups on their 90-day measures is a pre-specified analysis, and it publishes with the cohort aggregates rather than ahead of them.
The MAT Trap
Why Conventional Taper Fails, and What Ibogaine Does Differently
Medication-assisted treatment with methadone or buprenorphine is a clinically effective harm reduction strategy, but it carries a significant limitation: the medications themselves induce profound physical dependence, and discontinuation, even with a gradual taper, reliably produces a protracted withdrawal syndrome that can persist for months. This syndrome includes dysphoria, anhedonia, sleep disruption, muscular pain, intense drug craving, and a pervasive sense of emotional flatness that makes sustained abstinence extraordinarily difficult to maintain.
The neurobiological basis of this phenomenon is mu-opioid receptor downregulation. Chronic opioid agonist exposure causes the brain to reduce mu-opioid receptor density and sensitivity as a compensatory response. When the agonist is removed, even gradually, the resulting receptor deficit produces the withdrawal experience. Standard tapering reduces the magnitude of this deficit but does not address its neurobiological root cause. The brain's receptor system requires extended time to recalibrate, during which the patient must endure sustained psychological suffering.
Ibogaine operates through an entirely different mechanism. Its primary metabolite, noribogaine, acts as a long-acting opioid receptor normalizer, accelerating the restoration of mu-opioid receptor density and function while simultaneously modulating GDNF (glial cell line-derived neurotrophic factor) and BDNF pathways that underpin the brain's capacity to re-establish natural reward signaling. The result is a dramatic compression of the withdrawal timeline, reducing a months-long protracted syndrome to a matter of days, and a measurable reduction in craving that persists well beyond the acute pharmacological window.
What We Measure, And What Is Published
What is measured in this protocol, what the published literature reports, and when our own cohort figures become publishable.
Every guest in the MAT transition protocol is scored on the Clinical Opiate Withdrawal Scale (COWS, 0 to 48) and the Subjective Opiate Withdrawal Scale (SOWS, 0 to 64) from admission through the 90-day follow-up. Medication-free status is confirmed by prescriber contact and urine drug screening, never by self-report alone.
Methadone and suboxone guests are tracked as separate groups because their pharmacology differs: a full agonist with a 24 to 36 hour half-life against a partial agonist with higher receptor affinity. Pooling them would hide the one thing worth knowing.
Noller et al. (2017) reported 80% abstinence at one month in a New Zealand observational study of opioid dependence, and Brown & Alper (2017) synthesized 14 observational studies demonstrating consistent suppression of opioid withdrawal and craving. Those are published cohorts, not ours.
Craving, pain, sleep, and wellbeing each get their own Visual Analogue Scale alongside withdrawal, because anhedonia and emotional blunting are what guests on long-duration maintenance describe as the hardest part of a conventional taper.
Published studies consistently report resolution of acute opioid withdrawal within 24 to 48 hours after a single ibogaine treatment in a majority of patients. Whether a MAT transition cohort matches that window is a question our assessment schedule is designed to answer honestly.
More than 1,000 guests have been treated since 2019 with zero serious complications recorded. Cohort aggregates for this protocol publish at mindscaperetreat.com/outcomes once at least 20 people hold paired assessment data, and never before.
Clinical Protocol
14 to 18 Day MAT Transition Protocol
Comprehensive Screening & Dose Assessment
Every candidate undergoes a full medical and psychiatric evaluation before acceptance. This includes complete bloodwork, EKG with QTc interval measurement, cardiovascular history, liver function assessment (particularly relevant for long-term methadone patients), and a detailed medication history documenting current MAT dose, duration of maintenance, prior taper attempts, and concurrent medications. Patients with QTc prolongation above 450 ms, severe hepatic impairment, or active cardiac arrhythmia are not accepted for treatment.
Supervised Dose Reduction (2 to 3 Week Pretaper if Required)
Methadone patients above 40 mg/day and all suboxone patients complete a structured pretaper protocol before traveling to Cozumel. Methadone patients reduce to a target of 30 to 40 mg/day under the supervision of their prescribing physician, with our medical director providing remote guidance. Suboxone patients transition from buprenorphine to a short-acting opioid bridge (typically tramadol or codeine) over 5 to 7 days to allow buprenorphine clearance from mu-opioid receptors. This pretaper phase is non-negotiable, administering ibogaine without adequate receptor clearance risks treatment failure and potentially dangerous interactions.
Ibogaine Dosing: Test Dose Then Flood Dose
On the day of treatment, patients receive an initial test dose (typically 1 to 3 mg/kg ibogaine HCl) to assess individual sensitivity and cardiac response. Continuous EKG monitoring is maintained throughout. Following a 2 to 4 hour observation window, the full therapeutic flood dose is administered (typically 15 to 20 mg/kg total alkaloid or equivalent HCl dose, individualized by body weight and withdrawal severity). Some patients, particularly those with complex presentations or elevated cardiac sensitivity, receive staged dosing over 36 to 48 hours rather than a single flood dose, to balance therapeutic depth with cardiovascular safety.
Treatment with Continuous Cardiac & Withdrawal Monitoring
Throughout the 24 to 36 hour active treatment window, patients are under continuous physician and nursing supervision at MindScape Retreat's medically-equipped facility in Cozumel. Cardiac telemetry, oxygen saturation, and vital signs are monitored without interruption. Withdrawal symptoms, assessed using COWS, SOWS, and OOWS scales at 4-hour intervals, are actively managed with adjunctive supportive medications as needed. The therapeutic environment is intentionally calm, with individualized music, dim lighting, and dedicated care staff to support the depth and safety of the ibogaine experience.
Integration Therapy & 90-Day Aftercare with Relapse Prevention
Recovery from MAT does not end when the ibogaine experience concludes. Each patient receives a structured 90-day aftercare plan tailored to their individual history and risk profile. This includes: scheduled clinical check-ins at 7, 30, 60, and 90 days; referral to an integration-trained therapist in their home region; a written relapse prevention plan addressing high-risk triggers, emotional regulation strategies, and contingency protocols; and ongoing access to our medical director during the acute post-treatment window. Patients who require additional neurological or psychological support are referred to specialist aftercare providers within our clinical network.
Frequently Asked Questions
Questions About Ibogaine for Methadone & Suboxone
Peer-Reviewed References
Scientific literature informing the clinical methodology, pharmacological rationale, and outcome benchmarks for this cohort study.
Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46. doi:10.1080/00952990.2017.1310218
Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. Arch Gen Psychiatry. 2011;68(12):1238-1246. doi:10.1001/archgenpsychiatry.2011.121
Nosyk B, Sun H, Evans E, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment. J Addict Med. 2012;6(4):304-311. doi:10.1097/ADM.0b013e31825d32dc
Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36. doi:10.1080/00952990.2017.1320802
He DY, McGough NN, Ravindranathan A, et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci. 2005;25(3):619-628.
Glue P, Lockhart M, Gliese JE, et al. Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2015;55(2):189-194.
Mash DC, Kovera CA, Pablo J, et al. Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci. 2000;914:394-401.
Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden. Lancet. 2003;361(9358):662-668.
Every MindScape treatment program includes a guided 5-MeO-DMT (Bufo) ceremony, part of the all-inclusive price, not an add-on.